Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
2(22%)
Results Posted
25%(1 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_2
4
44%
Ph phase_1
5
56%

Phase Distribution

5

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
5(55.6%)
Phase 2Efficacy & side effects
4(44.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(4)
Terminated(2)
Other(1)

Detailed Status

Completed4
Terminated2
Active, not recruiting1
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
66.7%
Most Advanced
Phase 2

Trials by Phase

Phase 15 (55.6%)
Phase 24 (44.4%)

Trials by Status

active_not_recruiting111%
recruiting111%
unknown111%
completed444%
terminated222%

Recent Activity

2 active trials
Showing 5 of 9
active_not_recruitingphase_1

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

NCT03546426
recruitingphase_2

Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

NCT04115761
completedphase_2

Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma

NCT02677155
unknownphase_1

Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines

NCT02840123
completedphase_2

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

NCT01347034
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03546426Phase 1

Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies

Active Not Recruiting
NCT04115761Phase 2

Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients

Recruiting
NCT02677155Phase 2

Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma

Completed
NCT02840123Phase 1

Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines

Unknown
NCT01347034Phase 2

Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

Completed
NCT00576641Phase 1

Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma

Completed
NCT01006044Phase 2

Efficacy & Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme After Complete Surgical Resection

Completed
NCT00514189Phase 1

Feasibility Study of Acute Myelogenous Leukemia mRNA Plus Lysate Loaded Dendritic Cell Vaccines

Terminated
NCT00185874Phase 1

Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases

Terminated

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9